How is FOXO4-DRI different from dasatinib plus quercetin?

Dasatinib and quercetin work by inhibiting multiple survival pathways (tyrosine kinases, PI3K/AKT, anti-apoptotic proteins) that senescent cells depend on. This broad approach is effective but less selective. FOXO4-DRI targets a single protein interaction (FOXO4 binding to p53) that is largely absent in healthy cells, giving it over 11-fold selectivity in laboratory testing. The tradeoff is that D+Q has actual human clinical trial data while FOXO4-DRI does not.

Has FOXO4-DRI been tested in humans?

No. All published data comes from mouse studies and cell culture experiments. There are no completed human clinical trials. The peptide is available only as a research compound and is not approved for any medical use.

Why does a short treatment course produce long-lasting effects?

Senescent cells accumulate slowly over years. A short burst of FOXO4-DRI can clear the existing pool, and it takes months for new senescent cells to build back up to problematic levels. This is similar to how other senolytics are used in intermittent hit-and-run protocols rather than continuous dosing.

Could FOXO4-DRI affect healthy cells?

The FOXO4-p53 interaction that FOXO4-DRI targets is barely present in non-senescent cells. In laboratory testing, the peptide showed 11.73-fold selectivity for senescent versus healthy fibroblasts. Healthy cells showed no meaningful apoptosis at therapeutic concentrations.

What makes the D-retro-inverso design important?

Normal L-amino acid peptides are rapidly broken down by enzymes in the body, often within minutes. The DRI modification uses mirror-image D-amino acids in reverse order, which preserves the functional binding surface while making the peptide resistant to proteolytic degradation. This is what allows FOXO4-DRI to remain active long enough to reach and enter senescent cells.

Is FOXO4-DRI the same as the ES2 peptide?

No. ES2 is a next-generation senolytic peptide designed using computational modeling of the FOXO4-p53 interface. Published in 2021, it targets the CR3 domain of FOXO4 and was shown to be three to seven times more potent than FOXO4-DRI in laboratory and animal models. Both work through the same general mechanism but ES2 is a distinct molecule.

← All Peptides

FOXO4-DRI

Awaiting Reclassification

Clearing the cells that age forgot

A D-retro-inverso peptide that disrupts FOXO4 and p53 binding to clear senescent cells.

Educational content. This page describes FOXO4-DRI for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.

Primary Use: A D-retro-inverso peptide that disrupts FOXO4 and p53 binding to clear senescent cells.
Administration: injection
Typical Cycle: 5 days of treatment; effects assessed at 10 to 30 days
Legal Status: Awaiting Reclassification

Find a Provider

Key Benefits

Selective Senescent Cell Clearance

Targets and eliminates senescent cells with over 11-fold selectivity by disrupting the FOXO4-p53 survival interaction that exists almost exclusively in aged or damaged cells.[1][2]

Tissue Homeostasis Restoration

Restores organ function in aged mice, including improved kidney filtration, fur density, and physical fitness after just three doses over five days.[1]

Testosterone Recovery in Aging

Clears senescent Leydig cells in aged mice, increasing serum testosterone levels and restoring expression of steroidogenic enzymes like 3-beta-HSD and CYP11A1.[3][6]

Antifibrotic Potential

Reduces senescence-associated secretory phenotype factors and extracellular matrix overproduction in pulmonary fibrosis models, targeting senescent myofibroblasts.[4][5]

What is FOXO4-DRI?

FOXO4-DRI is a synthetic peptide designed to selectively eliminate senescent cells, the damaged or aged cells that stop dividing but refuse to die. It was developed by Peter de Keizer and colleagues at Erasmus University Medical Center in Rotterdam, first described in a 2017 Cell paper that became one of the most cited senolytic studies in the field.

The name reflects its design: it is a D-retro-inverso version of the FOXO4 protein segment that normally binds p53. By using D-amino acids assembled in reverse order, the peptide preserves the binding surface of the natural protein while gaining dramatic resistance to enzymatic breakdown. This makes it stable enough to function in living systems, unlike the native L-amino acid sequence that would be degraded within minutes.

How Does It Work?

In senescent cells, the transcription factor FOXO4 is selectively upregulated and acts as a survival switch. It physically sequesters the tumor suppressor p53 inside PML nuclear bodies, preventing p53 from reaching the mitochondria where it would trigger programmed cell death. Healthy, normally dividing cells express very little FOXO4, so this interaction is essentially absent outside of senescent populations.

FOXO4-DRI enters cells through a built-in cell-penetrating sequence and competes with endogenous FOXO4 for p53 binding. Because the peptide binds p53 with high affinity, it displaces the native FOXO4 and frees p53 from nuclear sequestration. The liberated p53 then translocates to the mitochondrial membrane.

At the mitochondria, p53 activates the pro-apoptotic protein BAX, which permeabilizes the outer mitochondrial membrane, releases cytochrome C, and initiates the caspase-3/7 cascade. The result is clean, intrinsic apoptosis of the senescent cell. Because healthy cells lack the FOXO4-p53 interaction, they are unaffected by the peptide.

Quick Facts

Clearing the cells that age forgot

Primary Use: A D-retro-inverso peptide that disrupts FOXO4 and p53 binding to clear senescent cells.
Administration: injection
Typical Cycle: 5 days of treatment; effects assessed at 10 to 30 days
Categories: senolyticanti aging
Legal Status: Awaiting reclassification

Find a Provider

Mechanism of Action

FOXO4-DRI competitively disrupts the FOXO4-p53 binding interaction that keeps senescent cells alive. By freeing p53 from nuclear sequestration, it allows p53 to translocate to mitochondria, activate BAX, and trigger caspase-dependent apoptosis selectively in senescent cells while sparing healthy tissue.

Clinical Evidence

Key studies supporting the therapeutic use of this peptide.

Targeted Senescent Cell Clearance Restores Tissue Homeostasis

Preclinical in vitro and in vivo studyIMR90 human fibroblasts; fast-aging XpdTTD/TTD mice and naturally aged wild-type mice

FOXO4-DRI showed 11.73-fold selectivity for senescent over healthy fibroblasts. In aged mice, three IP doses over five days restored kidney function, improved fur density, and increased physical fitness with no obvious adverse effects.

Baar MP, Brandt RMC, Putavet DA, et al. — Cell, 169(1):132-147.e16 (2017) · PubMed

Senescent Chondrocyte Clearance in Expanded Human Cartilage Cells

In vitro controlled studyHuman chondrocytes expanded to passage-induced senescence (PDL9) versus early-passage controls (PDL3)

25 micromolar FOXO4-DRI for five days eliminated over 50% of senescent chondrocytes while leaving non-senescent cells intact. SA-beta-gal staining and senescence markers were significantly reduced.

Huang Y, He Y, Makarcyzk MJ, Lin H — Front Bioeng Biotechnol, 9:677576 (2021) · PubMed

Testosterone Recovery Through Leydig Cell Senolysis

In vitro and in vivo controlled studyH2O2-induced senescent TM3 Leydig cells; naturally aged mice (20 to 24 months)

Three IP doses of 5 mg/kg cleared senescent Leydig cells and increased serum testosterone levels in aged mice. Expression of steroidogenic enzymes was restored when assessed 30 days after treatment.

Zhang H, Zhao C, Wang S, et al. — Aging (Albany NY), 12(2):1272-1284 (2020) · PubMed

Pulmonary Fibrosis Amelioration via Myofibroblast Targeting

In vivo mouse modelMice with bleomycin-induced pulmonary fibrosis

FOXO4-DRI targeted senescent myofibroblasts, reduced SASP factor secretion, decreased extracellular matrix overproduction, and improved fibrotic pathology.

Li Y, Luo S, et al. — J Cell Mol Med, 26(11):3269-3280 (2022) · PubMed

Dosing & Administration

Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.

Intraperitoneal Injection (Preclinical)

Dosage: 5 mg/kg body weight
Frequency: Every other day, 3 total doses
Cycle: 5 days of treatment; effects assessed at 10 to 30 days

Route	Dosage	Frequency	Cycle Length
Intraperitoneal Injection (Preclinical)	5 mg/kg body weight	Every other day, 3 total doses	5 days of treatment; effects assessed at 10 to 30 days

Intraperitoneal Injection (Preclinical): Used consistently across multiple mouse studies. Effects persisted for months after a single short course.

All published dosing data comes from mouse studies using intraperitoneal injection. No human pharmacokinetic or dose-finding data exists.

Allometric scaling from mouse IP suggests a rough human equivalent of approximately 0.4 mg/kg, but this has never been validated in clinical trials and should not be used for self-administration.

The short treatment course (three doses over five days) producing effects lasting months is a distinguishing feature of this peptide compared to other senolytics that require ongoing or monthly dosing.

Side Effects & Safety

Common

No adverse effects reported in mice — Published studies at 5 mg/kg IP reported no significant changes in body weight, organ weight, or liver and kidney function markers

Uncommon

Injection site reaction — Theoretical concern for any injectable peptide; not specifically reported in published literature

Rare

Excessive senescent cell clearance — Theoretical risk of removing transiently senescent cells that serve beneficial roles in wound healing or immune signaling

Safety Profile

The entire published safety profile is based on mouse studies. Baar et al. reported treating mice for over 10 months with repeated infusions three times per week without obvious adverse effects, but this level of safety data does not substitute for human trials.

No human pharmacokinetic, pharmacodynamic, or toxicology data has been published. The peptide remains strictly a preclinical research compound.

The D-retro-inverso design confers strong resistance to enzymatic degradation, which means the peptide persists longer in the body than a standard L-amino acid peptide. Long-term consequences of this stability in human tissue are unknown.

Contraindications

Active wound healing (senescent cells play transient beneficial roles in tissue repair)
Pregnancy (senescence signaling is involved in placental function and embryonic development)
Known TP53 pathway disorders such as Li-Fraumeni syndrome (unpredictable response to p53 liberation)
Immunocompromised individuals (clearance of apoptotic cell debris requires functional macrophage activity)
Children and adolescents (senescence plays roles in normal growth and development)

Compare with Similar Peptides

See how FOXO4-DRI compares to peptides with overlapping benefits.

Peptide	Primary Use	Administration	Cycle Length	Key Differentiator
FOXO4-DRI	Senolytic & Longevity	Injection	3 doses over 5 days (preclinical)	Highest demonstrated selectivity of any known senolytic, targeting a protein interaction found almost exclusively in senescent cells
SS-31 (Elamipretide)	Mitochondrial Restoration & Anti-Aging	Injection (daily)	Continuous (weeks to months)	Only peptide that directly targets cardiolipin on the inner mitochondrial membrane to restore electron transport chain efficiency
GHK-Cu	Anti-Aging & Recovery	Topical, Injection	8–12 weeks	Only peptide demonstrated to modulate ~31% of human genes, epigenetically resetting cellular function toward a younger phenotype
Sermorelin	Anti-Aging & GH Restoration	Injection (daily)	3–6 months	Only GHRH analog with FDA approval history and multi-decade safety record, uniquely preserving natural GH feedback
Glutathione	Antioxidant & Detoxification	IV, Oral, Sublingual	Ongoing supplementation	The body's own master antioxidant, with clinical data supporting oral bioavailability (challenging earlier assumptions) and dramatic immune cell activation at high doses

Regulatory Status

Current FDA classification and compounding eligibility.

Not Listed

503A Compounding

This substance does not appear on any FDA bulk drug substances list. It is classified as research-use only and cannot be legally compounded for human use.

Regulatory Detail

FOXO4-DRI does not appear on any FDA bulk drug substances list and is not FDA-approved for any indication. No human clinical trials have been published. It is a preclinical research peptide, and compounding pharmacies cannot legally produce it for human use. Available only through research programs.

What do these terms mean?

503A compounding: Licensed pharmacies that prepare custom prescriptions for individual patients based on a physician's order. 503A is the section of the federal law that governs them.
503B outsourcing: FDA-registered facilities that compound in larger batches under stricter federal oversight (closer to a manufacturer than a pharmacy). Used mostly by hospitals and clinics.
Bulk drug substance: The active pharmaceutical ingredient a compounder starts with, before it's made into a finished medication.
Category 1: Interim bucket for bulk substances that have been nominated and don't appear to present significant safety risks. 503A pharmacies may compound them under FDA enforcement discretion while the agency continues its review. Not the same as FDA approval.
Category 2: Bulk substances the FDA has flagged for significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare them and many physicians hesitate to prescribe them.
PCAC: Pharmacy Compounding Advisory Committee. The FDA advisory committee that reviews nominated bulk substances and recommends whether they belong in Category 1, Category 2, or on the final 503A Bulks List.

Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.

Frequently Asked Questions

Research & References

1
Baar MP, Brandt RMC, Putavet DA, et al. “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.” Cell, 169(1):132-147.e16 (2017)
PubMed DOI
2
Huang Y, He Y, Makarcyzk MJ, Lin H “Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.” Front Bioeng Biotechnol, 9:677576 (2021)
PubMed DOI
3
Zhang H, Zhao C, Wang S, et al. “FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency by Targeting Senescent Leydig Cells in Aged Mice.” Aging (Albany NY), 12(2):1272-1284 (2020)
PubMed DOI
4
Li Y, Luo S, et al. “FOXO4 Peptide Targets Myofibroblast Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice Through ECM-Receptor Interaction Pathway.” J Cell Mol Med, 26(11):3269-3280 (2022)
PubMed DOI
5
Li Y, Luo S, et al. “FOXO4-D-Retro-Inverso Targets Extracellular Matrix Production in Pulmonary Fibrosis.” Naunyn Schmiedebergs Arch Pharmacol, 396(10):2393-2403 (2023)
PubMed
6
Li Y, Zhang H, Wang Z, et al. “FOXO4-DRI Improves Spermatogenesis in Aged Mice Through Reducing Senescence-Associated Secretory Phenotype Secretion from Leydig Cells.” Exp Gerontol, 194:112522 (2024)
PubMed
7
Le HH, Cinaroglu SS, Manalo EC, et al. “Molecular Modelling of the FOXO4-TP53 Interaction to Design Senolytic Peptides for the Elimination of Senescent Cancer Cells.” EBioMedicine, 73:103646 (2021)
PubMed DOI

Ready to explore FOXO4-DRI therapy?

Looking into FOXO4-DRI? Find a provider who knows this peptide and can walk you through your options.

Find a Provider